RP Bio Inc. (KOSDAQ:314140)
South Korea
· Delayed Price · Currency is KRW 6,180.00
-30.00 (-0.48%)
At close: Apr 28, 2026
RP Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 136,219 | 123,967 | 151,046 | 138,109 | 114,964 | Upgrade
|
| Other Revenue | -0 | - | -0 | -0 | -0 | Upgrade
|
| Revenue | 136,219 | 123,967 | 151,046 | 138,109 | 114,964 | Upgrade
|
| Revenue Growth (YoY) | 9.88% | -17.93% | 9.37% | 20.13% | 17.40% | Upgrade
|
| Cost of Revenue | 122,407 | 116,783 | 135,487 | 120,355 | 102,052 | Upgrade
|
| Gross Profit | 13,812 | 7,184 | 15,560 | 17,754 | 12,912 | Upgrade
|
| Selling, General & Admin | 7,192 | 6,509 | 7,678 | 7,109 | 6,036 | Upgrade
|
| Amortization of Goodwill & Intangibles | 18.11 | 5.81 | 25.07 | 75.14 | 76.27 | Upgrade
|
| Other Operating Expenses | 426.63 | 538.68 | 533.92 | 447.05 | 410.13 | Upgrade
|
| Operating Expenses | 8,728 | 7,878 | 8,937 | 8,107 | 7,032 | Upgrade
|
| Operating Income | 5,084 | -693.64 | 6,623 | 9,647 | 5,880 | Upgrade
|
| Interest Expense | -829.23 | -1,251 | -1,796 | -1,184 | -979.22 | Upgrade
|
| Interest & Investment Income | 525.99 | 521.51 | 703.69 | 316.79 | 165.63 | Upgrade
|
| Currency Exchange Gain (Loss) | -26.67 | -1.04 | -11.69 | -29.51 | -1.84 | Upgrade
|
| Other Non Operating Income (Expenses) | 54.55 | 216.48 | 198.12 | -3,232 | -769.29 | Upgrade
|
| EBT Excluding Unusual Items | 4,808 | -1,208 | 5,717 | 5,519 | 4,295 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.59 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -178.59 | -9.24 | -59.74 | 150.06 | -4.31 | Upgrade
|
| Pretax Income | 4,631 | -1,217 | 5,658 | 5,669 | 4,291 | Upgrade
|
| Income Tax Expense | -50.91 | -309.88 | 220.38 | 1,353 | 478.26 | Upgrade
|
| Net Income | 4,682 | -907.12 | 5,437 | 4,316 | 3,813 | Upgrade
|
| Net Income to Common | 4,682 | -907.12 | 5,437 | 4,316 | 3,813 | Upgrade
|
| Net Income Growth | - | - | 25.99% | 13.20% | -17.40% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | 0.18% | -0.12% | 21.46% | 8.34% | -1.16% | Upgrade
|
| EPS (Basic) | 541.00 | -105.00 | 630.39 | 617.00 | 580.00 | Upgrade
|
| EPS (Diluted) | 541.00 | -105.00 | 582.00 | 606.00 | 580.00 | Upgrade
|
| EPS Growth | - | - | -3.96% | 4.48% | -16.43% | Upgrade
|
| Free Cash Flow | 7,276 | 7,670 | -543.31 | -3,992 | 2,213 | Upgrade
|
| Free Cash Flow Per Share | 840.66 | 887.85 | -62.81 | -560.54 | 336.69 | Upgrade
|
| Gross Margin | 10.14% | 5.79% | 10.30% | 12.86% | 11.23% | Upgrade
|
| Operating Margin | 3.73% | -0.56% | 4.38% | 6.98% | 5.12% | Upgrade
|
| Profit Margin | 3.44% | -0.73% | 3.60% | 3.13% | 3.32% | Upgrade
|
| Free Cash Flow Margin | 5.34% | 6.19% | -0.36% | -2.89% | 1.93% | Upgrade
|
| EBITDA | 11,495 | 6,124 | 12,671 | 15,050 | 11,083 | Upgrade
|
| EBITDA Margin | 8.44% | 4.94% | 8.39% | 10.90% | 9.64% | Upgrade
|
| D&A For EBITDA | 6,412 | 6,818 | 6,048 | 5,403 | 5,203 | Upgrade
|
| EBIT | 5,084 | -693.64 | 6,623 | 9,647 | 5,880 | Upgrade
|
| EBIT Margin | 3.73% | -0.56% | 4.38% | 6.98% | 5.12% | Upgrade
|
| Effective Tax Rate | - | - | 3.90% | 23.87% | 11.15% | Upgrade
|
| Advertising Expenses | 128.83 | 80.7 | 225.5 | 230.56 | 135.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.